Skip to main content
Kamisha L. Johnson-Davis, PhD, DABCC (CC, TC)
Medical Director: Clinical Toxicology
Professor (Clinical), University of Utah School of Medicine Specialties Therapeutic drug monitoring Drug screening Neonatal drug testing Trace and toxic elements Education Doctorate Degree—Pharmacology, University of Utah Postdoctoral Fellowship—Center for Human Toxicology Fellowship—Clinical Chemistry, University of Utah Certification/Affiliations American Board of Clinical Chemistry (Clinical Chemistry, Toxicological Chemistry) Certification of Qualification, New York State Department of Health Research Interests Assay development for drug testing by mass spectrometry and immunoassay Therapeutic drug monitoring in pediatric and adult patients Drug testing in alternative matrices and remote sampling Awards Travel Scholarship, AAMC Minority Faculty Career Development Seminar, 2014 International Travel Grant, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), 16th Congress, 2018 Recent Publications Masuda S, Lemaitre F, Barten MJ, et al. Everolimus personalized therapy: second consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology . Ther Drug Monit . 2024. Published online Sep 2024. Snozek CLH, Yee CI, Bryksin J, et al. Assessing knowledge gaps and educational needs in urine drug test interpretation among health care professionals . Am J Clin Pathol . 2024. Published online Jul 2024. Baryeh K, Zhou R, Brown E, et al. Retrospective data analysis reveals unusual metabolism pattern of ethanol in pediatrics as compared to adult and geriatric populations . J Appl Lab Med . 2024. Published online Jul 2024. McMillin GA, Morad AW, Boyd JM, et al. Biological testing and interpretation of laboratory results associated with detecting newborns with substance exposure . Clin Chem . 2024;70(7):934-947. Johnson-Davis KL, Ly D. Quantification of olanzapine by liquid chromatography-tandem mass spectrometry (LC-MS/MS) . Methods Mol Biol . 2024;2737:347-357. Johnson-Davis KL, Thomas RL. Quantification of oxcarbazepine using liquid chromatography-tandem mass spectrometry (LC-MS/MS) . Methods Mol Biol . 2024;2737:387-395. Pandya V, Wilker C, Johnson-Davis KL. Longitudinal trends in meconium drug detection in 46 US states between the years 2015 and 2020 . J Anal Toxicol . 2023;47(6):495-503. Okoye NC, Zuromski LM, Johnson-Davis KL. Trends in blood lead levels quantified by ICP-MS: a reference laboratory retrospective study . J Appl Lab Med . 2023;8(5):909-916. Lemaitre F, Budde K, Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19 . Ther Drug Monit . 2023;45(2):191-199. Smith K, Johnson-Davis KL, Shahrokh K. A new broad-spectrum drug screen for 127 analytes by LC-MS/MS . J Appl Lab Med . 2023;8(2):240-250. Bajaj AO, Parker R, Farnsworth C, et al. Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS) . J Mass Spectrom Adv Clin Lab . 2022;27:33-39. Bajaj AO, Ly D, Johnson-Davis KL. Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS . J Mass Spectrom Adv Clin Lab . 2022;24:100-106. Bajaj AO, Kushnir MM, Kish-Trier E, et al. LC-MS/MS method for measurement of thiopurine nucleotides (TN) in erythrocytes and association of TN concentrations with TPMT enzyme activity . Front Pharmacol . 2022;13:836812. Hunsaker JJH, La’ulu SL, LaGrave D, et al. Tobacco and cannabis use during pregnancy . Am J Clin Pathol . 2022;157(1):146-152. Clarke WA, Salyer B, Hussey C, et al. Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples . J Appl Lab Med . 2021;6(6):1541-1550. Okoye NC, Greene DN, Johnson-Davis KL. Is the confirmatory test always right? Sometimes immunoassays know what they are talking about . J Appl Lab Med . 2022;7(2):607-612. Kroner GM, Thomas RL, Johnson-Davis KL. Retrospective analysis of pediatric and adult populations using an LC-MS/MS method for oxcarbazepine/eslicarbazepine metabolite . J Appl Lab Med . 2021;6(3):637-644. Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology . Ther Drug Monit . 2021;43(2):150-200. McMillin GA, Johnson-Davis KL, Kelly BN, et al. Impact of the opioid epidemic on drug testing . Ther Drug Monit . 2021;43(1):14-24. Yang YK, Johnson-Davis KL, Kelly BN, et al. Demand for interpretation of a urine drug testing panel reflects the changing landscape of clinical needs; opportunities for the laboratory to provide added clinical value . J Appl Lab Med . 2020;5(5):858-868. Johnson-Davis KL, Farnsworth C, Law C, et al. Method validation for a multi-element panel in serum by inductively coupled plasma mass spectrometry (ICP-MS) . Clin Biochem . 2020;82:90-98.